Health Care [ 6/12 ] | Biotechnology [ 39/73 ]
NASDAQ | Common Stock
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide.
It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes.
In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; LYTENAVA to treat Opthamology; MEKINIST for cardiology; MINNEBRO for metabolic disease; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.
Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, JZP341, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; CE-furosemide for cardiology; CE-Meloxicam for neurology; V117, CX2101A, and Sitavig for infectious disease; REV-0100, OPT-302, and Reproxalap for opthamology; Vilazodone and Topiramate Injection for CNS; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder.
The company was incorporated in 1987 and is based in Jupiter, Florida.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 7, 25 | 1.60 Increased by +14.29% | 1.43 Increased by +11.89% |
| May 5, 25 | 1.33 Increased by +10.83% | 0.78 Increased by +70.51% |
| Feb 25, 25 | 1.27 Decreased by -7.97% | 1.19 Increased by +6.71% |
| Nov 7, 24 | 1.84 Increased by +80.39% | 1.35 Increased by +36.30% |
| Aug 6, 24 | 1.40 Decreased by -1.41% | 1.06 Increased by +32.08% |
| May 7, 24 | 1.20 Decreased by -47.37% | 0.78 Increased by +53.85% |
| Feb 27, 24 | 1.38 Increased by +1.47% | 0.66 Increased by +109.09% |
| Nov 8, 23 | 1.02 Decreased by -22.14% | 0.61 Increased by +67.21% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 25 | 47.63 M Increased by +14.68% | 4.85 M Increased by +109.34% | Increased by +10.18% Increased by +108.14% |
| Mar 31, 25 | 45.33 M Increased by +46.34% | -42.45 M Decreased by -149.28% | Decreased by -93.64% Decreased by -133.68% |
| Dec 31, 24 | 42.81 M Increased by +52.35% | -31.09 M Decreased by -270.93% | Decreased by -72.62% Decreased by -212.19% |
| Sep 30, 24 | 51.81 M Increased by +57.64% | -7.17 M Increased by +30.19% | Decreased by -13.84% Increased by +55.71% |
| Jun 30, 24 | 41.53 M Increased by +57.52% | -51.91 M Decreased by -2.37 K% | Decreased by -124.99% Decreased by -1.54 K% |
| Mar 31, 24 | 30.98 M Decreased by -29.56% | 86.14 M Increased by +105.34% | Increased by +278.07% Increased by +191.52% |
| Dec 31, 23 | 28.10 M Decreased by -44.22% | 18.19 M Increased by +225.14% | Increased by +64.72% Increased by +324.36% |
| Sep 30, 23 | 32.87 M Decreased by -50.27% | -10.27 M Decreased by -2.64 K% | Decreased by -31.26% Decreased by -5.21 K% |